Literature DB >> 34352722

Beneficial effect of dietary geranylgeraniol on glucose homeostasis and bone microstructure in obese mice is associated with suppression of proinflammation and modification of gut microbiome.

Eunhee Chung1, Moamen M Elmassry2, Jay J Cao3, Gurvinder Kaur4, Jannette M Dufour5, Abdul N Hamood6, Chwan-Li Shen7.   

Abstract

Geranylgeraniol (GGOH) is found in edible oils such as olive, linseed, and sunflower oils, which have favorable metabolic effects. However, it is unknown whether these physiological benefits are mediated through the gut microbiome. Thus, the purpose of this study was to test the hypothesis that GGOH supplementation would improve glucose homeostasis and benefit the bone microstructure in obese mice through suppression of inflammation and modification of gut microbiota composition. Thirty-six male C57BL/6J mice were divided into 3 groups: a low-fat diet, a high-fat diet (HFD), and an HFD supplemented with 800 mg GGOH/kg diet (GG) for 14 weeks. Glucose and insulin tolerance tests were measured at baseline and end of study. The concentrations of adipokine cytokines (resistin, leptin, monocyte chemoattractant protein-1, interleukin-6) were measured via ELISA. Bone microarchitecture and quality were measured by micro-CT. Microbiome analysis was performed using 16S rRNA amplicon sequencing on cecal content. Relative to the HFD group, the GG group: (1) improved glucose tolerance and insulin sensitivity; (2) reduced production of pro-inflammatory adipokines, (3) increased serum procollagen I intact N-terminal propeptide (bone formation marker) concentrations, while decreasing serum collagen type 1 cross-linked C-telopeptide (bone resorption marker) levels, and (4) increased stiffness at both femur and LV-4 and cortical thickness at femoral midshaft. Compared to the HFD group, the GG group had an increased abundance of Butyricicoccus pullicaecorum and decreased Dorea longicatena in the cecal microbiome. Collectively, GGOH improves glucose homeostasis and bone microstructure in obese mice, probably via suppression of pro-inflammation and modification of microbiome composition.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone health; Geranylgeraniol; Gut microbiome; Mevalonate pathway; Obesity; Type 2 diabetes mellitus

Mesh:

Substances:

Year:  2021        PMID: 34352722      PMCID: PMC8464510          DOI: 10.1016/j.nutres.2021.07.001

Source DB:  PubMed          Journal:  Nutr Res        ISSN: 0271-5317            Impact factor:   3.876


  49 in total

Review 1.  Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology.

Authors:  T Lemberger; B Desvergne; W Wahli
Journal:  Annu Rev Cell Dev Biol       Date:  1996       Impact factor: 13.827

2.  Effects of zoledronic acid and geranylgeraniol on angiogenic gene expression in primary human osteoclasts.

Authors:  Sobia Zafar; Mary P Cullinan; Bernadette K Drummond; Gregory J Seymour; Dawn E Coates
Journal:  J Oral Sci       Date:  2020       Impact factor: 1.556

3.  Vitamin K2 and geranylgeraniol, its side chain component, inhibited osteoclast formation in a different manner.

Authors:  Yuko Hiruma; Ken-ichi Nakahama; Hiroshi Fujita; Ikuo Morita
Journal:  Biochem Biophys Res Commun       Date:  2004-01-30       Impact factor: 3.575

Review 4.  Gut microbiome and type 2 diabetes: where we are and where to go?

Authors:  Sapna Sharma; Prabhanshu Tripathi
Journal:  J Nutr Biochem       Date:  2018-10-11       Impact factor: 6.048

5.  Metformin regulates osteoblast and adipocyte differentiation of rat mesenchymal stem cells.

Authors:  Ying Gao; Jing Xue; Xiaoyu Li; Yongqian Jia; Jing Hu
Journal:  J Pharm Pharmacol       Date:  2008-12       Impact factor: 3.765

6.  Beta-cell failure in diet-induced obese mice stratified according to body weight gain: secretory dysfunction and altered islet lipid metabolism without steatosis or reduced beta-cell mass.

Authors:  Marie-Line Peyot; Emilie Pepin; Julien Lamontagne; Martin G Latour; Bader Zarrouki; Roxane Lussier; Marco Pineda; Thomas L Jetton; S R Murthy Madiraju; Erik Joly; Marc Prentki
Journal:  Diabetes       Date:  2010-06-14       Impact factor: 9.461

7.  Thiazolidinediones on PPARγ: The Roles in Bone Remodeling.

Authors:  Wei Wei; Yihong Wan
Journal:  PPAR Res       Date:  2011-10-29       Impact factor: 4.964

8.  Specific gut microbiota features and metabolic markers in postmenopausal women with obesity.

Authors:  L K Brahe; E Le Chatelier; E Prifti; N Pons; S Kennedy; T Hansen; O Pedersen; A Astrup; S D Ehrlich; L H Larsen
Journal:  Nutr Diabetes       Date:  2015-06-15       Impact factor: 5.097

Review 9.  Obesity and Bone Health: A Complex Link.

Authors:  Jing Hou; Chen He; Wenzhen He; Mi Yang; Xianghang Luo; Changjun Li
Journal:  Front Cell Dev Biol       Date:  2020-12-21

Review 10.  The Impact of Type 2 Diabetes on Bone Fracture Healing.

Authors:  Carlos Marin; Frank P Luyten; Bart Van der Schueren; Greet Kerckhofs; Katleen Vandamme
Journal:  Front Endocrinol (Lausanne)       Date:  2018-01-24       Impact factor: 5.555

View more
  2 in total

Review 1.  New Advances in Improving Bone Health Based on Specific Gut Microbiota.

Authors:  Qihui Yan; Liping Cai; Weiying Guo
Journal:  Front Cell Infect Microbiol       Date:  2022-07-04       Impact factor: 6.073

Review 2.  The Role of Geranylgeraniol in Managing Bisphosphonate-Related Osteonecrosis of the Jaw.

Authors:  Kok-Yong Chin; Sophia Ogechi Ekeuku; Anne Trias
Journal:  Front Pharmacol       Date:  2022-05-04       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.